Cytocell Ltd is a leading European developer and manufacturer of FISH probes for use in both routine cytogenetics and in the analysis and classification of cancers. Recently, the company has focused on developing products for oncology and now has a catalogue of some 350 products for cytogenetics, haematology and solid tumour analysis as well as developing custom FISH probes for customers with specific interests under the myProbes® brand. Cytocell’s products are available through a well established distributor network, covering more than 60 countries worldwide. Cytocell’s FISH probe service is currently proving to be invaluable to cancer researchers and clinicians worldwide.
No data available
No data available
DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells ( Opti-Heps) with functional relevance comparable to human primary cells.
Our Opti-Heps effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our Opti-Heps successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.
Our Opti-Heps effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our Opti-Heps successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.
Deloitte is the UK's fastest growing professional services firm in locations across the UK, with over 10,000 staff worldwide. Deloitte offers integrated services including audit, tax, consulting and corporate finance. Our approach combines insight and innovation from multiple disciplines with business and industry knowledge to help our clients excel anywhere in the world. We deliver outstanding impact on the reputation and success of our clients, in the UK and globally. Our industry specialists from across Deloitte provide an extensive depth of knowledge on the range of current issues experienced by the pharmaceuticals, biotechnology, medical devices and private healthcare industries.
Discovery Park in Sandwich, Kent is a global leader for science and enterprise with world class laboratories and exceptional office space. The site has a track record for drug discovery stretching back to the 1950’s and continues to lead the way in R&D from the search for new antibiotics to pioneering research across the life sciences; from developing new therapeutics and diagnostics to unlocking the full potential of immunotherapy and immuno-oncology.
As well as industry-leading laboratories for R&D and bespoke office space, we can help businesses searching for the right location to manufacture their products or store with our bespoke warehousing options – all in a stunning, collaborative and inspirational campus environment. Thanks to Enterprise Zone status, businesses can also access a range of benefits – from free Wi-fi and funding advice to streamlined planning.
Whether you’re looking for start-up space to launch your business venture or a global headquarters for your company, we have all you need at Discovery Park to take your business to the next level.
As well as industry-leading laboratories for R&D and bespoke office space, we can help businesses searching for the right location to manufacture their products or store with our bespoke warehousing options – all in a stunning, collaborative and inspirational campus environment. Thanks to Enterprise Zone status, businesses can also access a range of benefits – from free Wi-fi and funding advice to streamlined planning.
Whether you’re looking for start-up space to launch your business venture or a global headquarters for your company, we have all you need at Discovery Park to take your business to the next level.
Strategic Expertise, Operational Excellence.. . A forward thinking regulatory affairs consultancy with more than 250 cumulative years regulatory experience spanning many therapeutic specialities. We offer the full range of regulatory affairs services from strategic advice in early drug development, to compilation and management of regulatory submissions, and for over 10 years we have helped companies of all sizes and backgrounds maximise the commercial value of their product. We also understand the importance of a clear regulatory strategy and pathway to market which can maximise the value of an asset when negotiating out-licensing agreements, and our proactive collaborative interactions with Regulatory Authorities can improve chances of approval of a product in the optimal time.
No data available
Domainex offers services including highly experienced computational and medicinal chemistry and a unique patented technology called CDH. . . Our unique LeadBuilder technology for finding in a highly cost effective manner robust developable hits. LeadBuilder has been used many times for clients in the academic or biotech areas with great effect. Our medicinal chemistry expertise is based upon a team of highly experienced medicinal chemists based in Cambridge with a history of working for leading European Pharma and Biotech. We specialise in tackling a broad range difficult targets for drug discovery, including peptidomimetics.. . Combinatorial Domain Hunting or CDH is a unique patented technology conceived by Prof Laurence Pearl’s team of leading structural biologists and is specifically aimed at expressing protein targets for drug discovery that can not be expressed by other approaches. CDH has been applied to targets from many leading Pharma.. . Domainex also has its own drug discovery pipeline. Domainex’s lead project is IKK epsilon which is in lead optimisation for breast cancer. Domainex also has a pipeline of lysine methyl transferases (KMTs) all targeted at cancer. Our unique CDH technology has been applied to a number of KMTs with the aim of producing unique x-ray structures and assays.
I am a freelance consultant and a science and medical writer. I trained in physics before switching to biophysics for my PhD (later bioinformatics) and spent nine years as a postdoctorate in the UK and US before changing careers in 1998. I still teach to MSc level; bioinformatics and structural biology at Birkbeck, University of London and medicinal chemistry at the Opeu University. I write news and features in print and online for a specialist scientific and medical readership; provide specialist editing services; and offer support, training and capacity building in bioinformatics and related subjects within academia and industry.